New hope for CLL patients who Can't tolerate standard treatment
NCT ID NCT02717611
First seen Jan 08, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This study tests a drug called acalabrutinib (ACP-196) in 60 adults with chronic lymphocytic leukemia (CLL) that has come back or not responded to treatment, and who had side effects from ibrutinib. The main goal is to see how many people's tumors shrink or disappear. Participants take the drug by mouth and are followed for disease progression and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Tucson, Arizona, 85704, United States
-
Research Site
Concord, California, 94520, United States
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Palo Alto, California, 94304, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Lake Success, New York, 11042, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Sherman, Texas, USA, United States
-
Research Site
Seattle, Washington, 98108, United States
-
Research Site
Seattle, Washington, 98122, United States
-
Research Site
Spokane, Washington, 99208, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States
-
Research Site
Bruges, 8000, Belgium
-
Research Site
Bordeaux, 33076, FR, France
-
Research Site
Haifa, 31000, Israel
-
Research Site
Madrid, 28006, Spain
-
Research Site
Bournemouth, BH7 7DW, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
Conditions
Explore the condition pages connected to this study.